Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Background In patients with ST-segment elevation myocardial infarction (STEMI) with
multivessel coronary artery disease, the time at which complete revascularization of …

for digital applications (smartphones, etc.). These versions are abridged and thus, for more
detailed information, the user should always access to the full text version of the guidelines …

The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has
been granted authorization or approval in several countries for the treatment of patients with …

1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

Background The appropriate duration of dual antiplatelet therapy in patients at high risk for
bleeding after the implantation of a drug-eluting coronary stent remains unclear. Methods …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with …